Syndax Pharmaceuticals Inc (SNDX): Cash & Equivalents
$134.93M
As of 2025-12-31
$336.48M
As of 2026-06-30
+22.0%
3-year compound annual growth
+3.2%
5-year compound annual growth
+19.3%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $134.93M | -12.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $154.08M | -47.8% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $295.39M | +297.3% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $74.36M | -66.5% | 2025-03-03, Balance as of period end |
| 2021-12-31 | $221.97M | +92.6% | 2024-02-27, Balance as of period end |
| 2020-12-31 | $115.24M | +368.3% | 2023-02-28, Balance as of period end |
| 2019-12-31 | $24.61M | -27.1% | 2022-03-01, Balance as of period end |
| 2018-12-31 | $33.77M | -4.0% | 2021-03-12, Balance as of period end |
| 2017-12-31 | $35.17M | +47.5% | 2020-03-05, Balance as of period end |
| 2016-12-31 | $23.84M | +2.9% | 2019-03-07, Balance as of period end |
| 2015-12-31 | $23.18M | +131.6% | 2018-03-08, Balance as of period end |
| 2014-12-31 | $10.01M | n/a | 2017-03-14, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $134.93M | -12.4% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | $129.97M | -56.3% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $250.49M | +633.8% |
| Lifevantage Corp (LFVN) | 2025-06-30 | $20.20M | +19.6% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $84.22M | -34.2% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $216.89M | -32.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $190.68M | +8.0% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $54.30M | -39.1% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $28.65M | +11.0% |
Compare SNDX, PHAT, CYRX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗